Ankylosing Spondylitis
📧 Sign up to get email alerts when something new happens for Ankylosing Spondylitis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-11-08FDA Approved: CIMZIA — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for CIMZIA (certolizumab pegol) from UCB, Inc., updating its labeling and/or indications.
-
FDA approval · 2023-11-03FDA Approved: HUMIRA — Supplemental Application (Cordavis Limited)
FDA approves a supplemental application for HUMIRA (adalimumab) to Cordavis Limited, enabling an additional manufacturing/supply pathway for…
-
CLINICAL_TRIALS trial_result · 2023-10-27Clinical Trial Update: A Study of LNK01001 Capsule in Patients With Ankylosing Spondylitis [Phase 2]
Phase 2 clinical trial update for LNK01001 capsule in patients with ankylosing spondylitis has completed.
-
FDA approval · 2023-10-20FDA Approved: ZYMFENTRA — Original Application (CELLTRION USA Inc.)
FDA approved ZYMFENTRA (inflximab-dyyb) from Celltrion USA as a biosimilar to infliximab (Remicade), based on demonstration of biosimilarity…
-
FDA approval · 2023-10-18FDA Approved: ENBREL — Supplemental Application (Immunex Corporation)
The FDA approved a supplemental application for Enbrel (etanercept) submitted by Immunex Corporation.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-10-11FDA Approved: NAPROXEN AND ESOMEPRAZOLE MAGNESIUM — Original Application (ScieGen Pharmaceuticals, Inc)
FDA approved Naproxen and Esomeprazole Magnesium (ScieGen Pharmaceuticals) under Original Application. The combination is indicated for reli…
-
FDA approval · 2023-09-21FDA Approved: ADALIMUMAB — Supplemental Application (CELLTRION USA, Inc.)
FDA approved a supplemental Biologics License Application for the adalimumab biosimilar ADALIMUMAB-AATY from Celltrion USA, approving its bi…
-
FDA approval · 2023-09-07FDA Approved: INDOMETHACIN — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for Indomethacin submitted by Amneal Pharmaceuticals LLC.
-
CLINICAL_TRIALS trial_result · 2023-08-01Clinical Trial Update: Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis [Phase 2]
This Phase 2 trial update reports results from a study evaluating the effect of Filgotinib on semen parameters in adult males with active rh…
-
CLINICAL_TRIALS trial_result · 2023-07-27Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Ankylosing Spondylitis [Phase 2, Phase 3]
A phase 2/3 clinical trial evaluating the efficacy and safety of SHR0302 in patients with ankylosing spondylitis has completed.
-
CLINICAL_TRIALS trial_result · 2023-07-27Clinical Trial Update: A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis [Phase 2]
Phase 2 trial evaluating bimekizumab and certolizumab pegol in active ankylosing spondylitis has completed with results posted.
-
FDA approval · 2023-07-24FDA Approved: COSENTYX — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Cosentyx (secukinumab) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2023-07-19FDA Approved: ADALIMUMAB-ADBM — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
The FDA approved a supplemental application for ADALIMUMAB-ADBM, a biosimilar of adalimumab from Quallent Pharmaceuticals Health LLC.
-
FDA approval · 2023-06-30FDA Approved: ADALIMUMAB-ADBM — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
The FDA approved a supplemental application for the adalimumab biosimilar ADALIMUMAB-ADBM from Quallent Pharmaceuticals Health LLC.
-
FDA approval · 2023-05-23FDA Approved: ADALIMUMAB — Original Application (CELLTRION USA, Inc.)
FDA approved ADALIMUMAB-AATY from CELLTRION USA, Inc. as a biosimilar to adalimumab under an Original Application for the same indications a…
-
FDA approval · 2023-05-18FDA Approved: ADALIMUMAB-ADBM — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
FDA approved a supplemental application for ADALIMUMAB-ADBM, a biosimilar to adalimumab, from QUALLENT PHARMACEUTICALS HEALTH LLC.
-
FDA approval · 2023-04-14FDA Approved: ADALIMUMAB — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for adalimumab-adaz, a biosimilar to adalimumab, confirming its regulatory approval for use.
-
FDA approval · 2023-03-31FDA Approved: YUSIMRY — Supplemental Application (Coherus BioSciences Inc)
FDA approved a supplemental Biologics License Application for YUSIMRY (adalimumab-aqvh) by Coherus BioSciences, authorizing the biosimilar p…
-
CLINICAL_TRIALS trial_result · 2023-03-29Clinical Trial Update: Jaktinib Hydrochloride Tablets In The Treatment of Active Ankylosing Spondylitis [Phase 2]
Phase 2 clinical trial update for jaktinib hydrochloride tablets in active ankylosing spondylitis has been completed.
-
CLINICAL_TRIALS trial_result · 2023-03-09Clinical Trial Update: Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar) [Phase 3]
Phase 3 trial comparing the effect of secukinumab on radiographic progression in Ankylosing Spondylitis vs an adalimumab biosimilar (GP2017)…
-
CLINICAL_TRIALS trial_result · 2023-01-25Clinical Trial Update: National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life
A national observational study assessing the real-world use of Inflectra (infliximab biosimilar) across multiple inflammatory diseases compl…
-
CLINICAL_TRIALS trial_result · 2023-01-20Clinical Trial Update: A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis [Phase 4]
Phase 4 clinical trial evaluating golimumab in Indian participants with active ankylosing spondylitis or psoriatic arthritis has completed. …
-
FDA approval · 2022-11-16FDA Approved: AZULFIDINE EN-TABS — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for Azulfidine En-Tabs (sulfasalazine) filed by Pfizer Laboratories Div Pfizer Inc.
-
FDA approval · 2022-10-28FDA Approved: NAPROXEN SODIUM — Original Application (Camber Consumer Care Inc)
FDA approved Naproxen Sodium generic from Camber Consumer Care Inc under an Original Application (ANDA211065).
-
FDA approval · 2022-10-06FDA Approved: NAPROXEN AND ESOMEPRAZOLE MAGNESIUM — Original Application (Ajanta Pharma USA Inc.)
FDA approved Ajanta Pharma USA Inc.'s Naproxen and Esomeprazole Magnesium as an Original Application (ANDA213699), providing a generic versi…